Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 155 от 240

Предстои набиране Фаза 3

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Early Breast Cancer

The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI) intolerance. Giredestrant will be administered as adjuvant endocrine therapy for participants with low-, medium-, and high-risk, Stage I-III, histologically confirmed, estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (eBC), as defined by the investigator. Participants will enroll if considered to be intolerant to a prior adjuvant AI therapy.

Начало: 30.06.2026 Край: 30.06.2034 Възраст: от 18 г.

Genentech, Inc. NCT07541079

Предстои набиране Фаза 3

Nitazoxanide for Treatment of Cryptosporidium in Children

Cryptosporidiosis

The goal of this clinical trial is to learn if nitazoxanide (NTZ) can treat Cryptosporidium infection in children age 6-12 months. The main questions it aims to answer are: * Does NTZ treatment of diarrheal Cryptosporidium infection lower the number of days of diarrhea? * Does NTZ treatment of diarrheal and non-diarrheal Cryptosporidium infection lower the number of days that parasites can be found in the stool? Researchers will compare NTZ to a placebo (a look-alike substance that contains no drug) to see if NTZ works to treat Cryptosporidium. Participants will: * Take NTZ or placebo for 3 days * Receive regular visits from field research assistants * Provide blood and urine samples

Начало: 30.06.2026 Край: 01.05.2030 Възраст: 6–12 г.

Johns Hopkins Bloomberg School of Public Health NCT06600711

Предстои набиране

An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States

Vasomotor Symptoms (VMS) Associated With Menopause

Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life harder. Elinzanetant is a new, hormone free medicine that works by blocking certain signals in the brain that are linked to these symptoms. It has already been shown in clinical studies to help reduce hot flashes. This study is being done to learn about how elinzanetant is used, how well it works, and how safe it is for women with menopause symptoms in real-world, everyday medical care. The main goal is to understand who is starting treatment with elinzanetant and what symptoms they have. The study will also look at how well elinzanetant helps with hot flashes, night sweats, and sleep problems, how safe it is, how satisfied women are with the treatment, and how it affects their quality of life and daily activities. To do this, researchers will follow about 1,500 women in the United States who are starting elinzanetant as part of their usual care. Women will answer questions about their symptoms, sleep, and daily life using a secure app on their phone or computer. Some women will also wear a smart ring for a few weeks to collect information about their sleep. The study will last about 12 weeks for most women, but some will be followed for up to 2 years. No extra treatments or tests will be given as part of the study-researchers will only collect information about how women are doing while taking elinzanetant as prescribed by their own doctor. The results will help doctors and patients understand how elinzanetant works in real life and support better care for women going through menopause.

Начало: 30.06.2026 Край: 30.06.2029

United States Bayer NCT07490431

Предстои набиране

Postural Motor Activation Deficits After mTBI; Translating Laboratory Findings to Clinical Care

Mild Traumatic Brain Injury (mTBI) Concussion, Mild Traumatic Brain Injury

This work will address an important gap in physical therapy rehabilitation after concussion. Physical therapy usually focuses on how the brain processes sensory information such as inner ear and vision for balance rehabilitation, but our recent research shows that people with imbalance more often have a problem with how they can respond to imbalance (i.e., motor activation). While there are complex laboratory tools to test motor activation for balance, these tests are not practical for the clinic. Our goal is to create both an exercise intervention focused on motor activation after concussion and simple, but objective and instrumented (wearable sensors), clinical measures of motor activation. Objectives: This research study has three aims. 1) We will develop an exercise program to improve the problems with how one's body responds to imbalance (i.e., improve motor activation) after a concussion. We will do this using a Community Based Participatory Research (CBPR) approach by collaborating with a team of people with a broad range of experience related to concussion. We will include patients who have had a concussion, healthcare professionals with expertise in concussion, and healthcare administrators. This group will contain people working in the military and civilians. 2) We will compare our new motor-focused physical therapy intervention to the standard sensory focused balance intervention. We will determine which intervention program is more effective in treating balance problems after a concussion. We hypothesize that the motor-focused program will help patients more compared to the sensory program. 3) We will create and test several balance tests that can be used in the clinical without expensive research equipment to our standard research-based motor activation tests. This aim will allow us to determine if the clinical tests perform as well as the research-grade tests. To make the test useful to clinicians, we will use simpler technology like smart-phone applications, wearable sensors, and virtual reality goggles that are both affordable and practical for healthcare providers.

Начало: 30.06.2026 Край: 30.08.2029 Възраст: 18–60 г.

United States Oregon Health and Science University NCT07549529

Предстои набиране Фаза 2

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Large B-cell Lymphoma Hodgkin Lymphoma

This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.

Начало: 28.06.2026 Край: 30.09.2033 Възраст: 18–75 г.

United States M.D. Anderson Cancer Center NCT07164469

Предстои набиране

The Effect Of Motıvatıonal Intervıewıng On Cancer Fear And Partıcıpatıon In Cervıcal Cancer Screenıngs Among Women Lıvıng In Rural Areas

Fear

This research was conducted to determine the effect of a motivational interview-based nursing care program on health beliefs and cancer fears related to cervical cancer and screening in rural women.

Начало: 27.06.2026 Край: 02.09.2026 Възраст: 30–65 г.

Ozge Aslan Koyutürk NCT07540962

Предстои набиране Фаза 2

Cannabis for Obesity Trial

Obesity

The goal of this study is to determine the initial efficacy of once daily oral cannabis for weight loss in obese individuals.

Начало: 21.06.2026 Край: 31.03.2028 Възраст: 18–65 г.

Joshua A. Lile, Ph.D. NCT06137365

Предстои набиране

Effect of Anal Lift Exercise on Rehabilitation After Anal Fistula Surgery

Kegel Exercises

This prospective randomized controlled study aims to include patients who have undergone anal fistula surgery, to observe the impact of early postoperative pelvic floor muscle training combined with dietary intervention on postoperative pain, bleeding, anal distension and defecation function, with the goal of clarifying the value of early rehabilitation intervention in the recovery after anal fistula surgery, and providing a reference for optimizing postoperative management plans in clinical practice.

Начало: 20.06.2026 Край: 30.06.2026 Възраст: 18–55 г.

China The Affiliated Hospital of Putian University NCT07250711

Предстои набиране

Development of Multidimensional Screening Tool for WMSDs

Work-Related Musculoskeletal Disorders Musculoskeletal Diseases Occupational Diseases

The purpose of this study is to develop a multidimensional screening tool for Work-Related Musculoskeletal Disorders (WMSDs) and to evaluate its psychometric properties. The study involves a cross-sectional survey of approximately 250 workers in the bio-pharmaceutical industry to assess the tool's structural validity, internal consistency, construct validity, and measurement invariance following COSMIN guidelines.

Начало: 20.06.2026 Край: 31.12.2026 Възраст: 19–65 г.

South Korea Sahmyook University NCT07367646

Предстои набиране Фаза 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy

Narcolepsy

The primary objective of this study is to evaluate the effect of Samelisant on excessive daytime sleepiness (EDS) after 12 weeks of treatment. In addition, the study aims to assess its effectiveness in influencing the weekly frequency of cataplexy episodes (sudden bouts of muscle weakness) that occur while the individual remains conscious. Other objectives include examining the impact of Samelisant on attention and alertness, overall quality of life, the spectrum of narcolepsy symptoms, and daily functioning, as well as evaluating its safety profile.

Начало: 19.06.2026 Край: 19.12.2027 Възраст: от 18 г.

Suven Life Sciences Limited NCT07540364

Предстои набиране Фаза 2

A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.

Uveitis

This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.

Начало: 18.06.2026 Край: 13.01.2028 Възраст: от 18 г.

China Changchun GeneScience Pharmaceutical Co., Ltd. NCT07547995

Предстои набиране Фаза 1

A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Small Cell Carcinoma of Lung

Lung cancer remains the leading cause of cancer deaths worldwide; in 2022, there were approximately 2.48 million new cases and 1.8 million deaths from lung cancer globally. Globally, lung cancer is the leading cause of cancer-related deaths in men and the second leading cause in women after breast cancer. Among them, small cell lung cancer (SCLC) accounts for approximately 14% of all newly diagnosed lung cancers. Small cell lung cancer (SCLC) is a highly heterogeneous and aggressive disease with poor survival outcomes. A 2-stage system dividing patients into limited and extensive disease was developed in 1973 by the United States (US) Veteran's Administration Lung Cancer Study Group (VALG), which has been used to this day. Patients with limited-stage SCLC can be treated with chemotherapy and radiation with the potential for long-term survival. However, the majority (approximately 70%) of patients with SCLC are diagnosed with extensive-stage SCLC (ES-SCLC), which has poor survival prospects. Chest pain, dyspnea, and cough are among the most frequent disease-related symptoms experienced by patients with SCLC. Immune checkpoint inhibitors in combination with platinum-based systemic therapy can palliate symptoms and prolong survival for patients with ES-SCLC. However, long-term survival is rare. The current standard first-line treatment for patients with ES-SCLC is immune checkpoint inhibitors in combination with platinum-based systemic therapy. Despite the impressive high objective response rates (approximately 60%-80%) observed with first-line treatment regimens, the median overall survival (OS) of patients rarely exceeds 16 months, and the median progression-free survival (PFS) is also limited to around 5 months. Second-line and subsequent therapeutic options are limited. The main treatment drugs include Topotecan, Lurbinectedin, Tarlatamab, etc., with objective response rates rarely exceeding 40%. Therefore, there is a significant need for improved novel treatment options for patients with ES-SCLC. This is a multi-center, open-label study. The study is designed to evaluate the safety, tolerability, and preliminary efficacy of Toripalimab in combination with BL0020 in patients with ES-SCLC who have relapsed or progressed following first-line platinum-based systemic treatment regimen.

Начало: 16.06.2026 Край: 18.08.2028 Възраст: от 18 г.

China Shanghai Best-Link Bioscience, LLC NCT07550842

Предстои набиране

IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA

Revision Total Knee Arthroplasty

Purpose of this study is to compare the efficacy of intravenous and intraosseous antibiotic administration techniques during revision total knee arthroplasty

Начало: 15.06.2026 Край: 15.06.2030 Възраст: от 18 г.

The Methodist Hospital Research Institute NCT07283068

Предстои набиране Фаза 3

A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker delta-like ligand 3 (DLL3). Participants are put into 2 groups randomly, which means by chance. One group (treatment arm) receives obrixtamig and standard chemotherapy followed by obrixtamig alone for up to 3 years. The other group (control arm) receives standard chemotherapy without obrixtamig for about 4 months. All treatments are given as infusions into a vein. During the study, participants in both groups visit the study site regularly. Participants in the treatment arm stay overnight at the study site following the first 2 obrixtamig treatments. The doctors regularly check participants' health and take note of any unwanted effects. At some of the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works.

Начало: 15.06.2026 Край: 15.05.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Austria +25 Boehringer Ingelheim NCT07544654

Предстои набиране

Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France

Hematological Malignancies

Integrative medicine promotes the incorporation of elements from complementary and alternative medicines (CAM) into patient care. These approaches are defined as treatments that are not routinely part of conventional medical care (1). CAM practices include osteopathy, acupuncture, aromatherapy, naturopathy, and various energy-based techniques, although their efficacy is not always well-established. Nevertheless, a meta-analysis on the use of CAM in the context of cancer reported a 40% prevalence of use in 2012 (2). Subsequently, a study conducted in France in 2015 revealed an 83% prevalence of CAM use across all types of cancer, underscoring the interest in these therapies (3). CAM is often employed to alleviate side effects of conventional treatments, such as fatigue, nausea, and vomiting. The 2015 French study primarily focused on solid tumors, with hematological malignancies representing only 2% of the cases, thereby limiting the assessment of CAM use in this context (3). Currently, there is no specific data evaluating the use of CAM among patients with hematological malignancies in France. Hematological malignancies, unlike solid tumors, are characterized by their diffuse nature, making their localization and treatment more challenging for patients to comprehend (4). Additionally, a qualitative study the investigators conducted on the spiritual needs of patients recently diagnosed with hematological malignancies identified CAM as an area of interest. Among the ten patients in the study, seven were using CAM and reported an improvement in their spiritual well-being, which is defined as the ability to integrate the meaning and purpose of life into their health experiences, through relationships with themselves, others, art, nature, or a higher entity. This aspect of CAM utilization was not explored in our previous study on the spiritual needs of patients, particularly in understanding their appeal and the motivations of patients to adopt them. Therefore, it appears crucial to explore this practice, which is known to be common among healthcare providers. Understanding these complementary care pathways would enable their safety (e.g., avoiding or informing about potential drug interactions) and foster the patient-provider relationship around a topic that is sometimes considered taboo (5). Ultimately, this would contribute to better supporting patients within a holistic care perspective.

Начало: 15.06.2026 Край: 15.12.2027 Възраст: от 18 г.

France University Hospital, Limoges NCT07541326

Предстои набиране

Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis

Geriatric Anesthesia Postop Adult ICU Patients

The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.

Начало: 15.06.2026 Край: 30.07.2026 Възраст: от 65 г.

Malatya Egitim Ve Arastirma Hastanesi NCT07544719

Предстои набиране

Improving Self-Care of Caregivers of Adults in Homecare With Heart Failure and Cognitive Impairment

Heart Failure Cognitive Impairment Caregiver Burden

This RCT design will enroll 254 informal caregivers (spouse/partner or child) of HHC patients with HF/CI and 60 patients with HF and mild to moderate CI (60 dyads). After collecting baseline data, we will block randomize the caregivers 1:1 to the ViCCY intervention or comparator group, stratifying randomization by caregiver sex (male/female), relationship (spouse/partner or child), and race (white/other)- factors known to influence caregiving burden, perceived stress, and receptivity to the intervention. We will encourage caregivers to use their own devices but provide tablet devices with wireless network access if needed. The intervention group will receive 10 sessions of ViCCY over 6 months.

Начало: 15.06.2026 Край: 15.09.2029 Възраст: 18–101 г.

Visiting Nurse Service of New York NCT07220798

Предстои набиране

Human Experimental Models of Pain (HEMP)

Acute Pain

This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain. The study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen). Up to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit. The study includes several experimental pain tests. These include: a heat and capsaicin skin test that causes short-term skin sensitivity, a UVB light test that causes a temporary sunburn-like sensitivity, and a cold pressor test, in which a hand is placed in very cold water for a short time. Participants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done. Each treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks. This study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....

Начало: 15.06.2026 Край: 31.12.2030 Възраст: 18–100 г.

United States National Center for Complementary and Integrative Healt NCT07549490

Предстои набиране Фаза 1

A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

This study is an open-label, first-in-human Phase I clinical study to evaluate the safety, tolerability, PK characteristics, and preliminary antitumor activity of HLX316 in participants with advanced/metastatic solid tumors. The study will consist of 2 parts: a Phase Ia dose-escalation part and a Phase Ib dose-expansion part. Phase Ia and Phase Ib will focus on exploring the preliminary antitumor activity of HLX316 in participants with platinum-resistant ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Начало: 10.06.2026 Край: 01.06.2029 Възраст: от 18 г.

China Shanghai Henlius Biotech NCT07541534

Предстои набиране Фаза 1/2

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.

Начало: 09.06.2026 Край: 30.10.2029 Възраст: от 18 г.

China, United States Avistone Biotechnology Co., Ltd. NCT07538804

1 … 153 154 155 156 157 … 240